Phathom Pharmaceuticals (PHAT)
(Delayed Data from NSDQ)
$12.21 USD
+0.39 (3.30%)
Updated Oct 3, 2025 04:00 PM ET
After-Market: $12.30 +0.09 (0.74%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Return on Equity (TTM)
Phathom Pharmaceuticals, Inc.'s return on equity, or ROE, is -930.09% compared to the ROE of the Medical - Biomedical and Genetics industry of -59.35%. While this shows that PHAT has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
PHAT 12.21 +0.39(3.30%)
Will PHAT be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for PHAT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHAT
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's Why
Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High?
PHAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
MannKind (MNKD) Reports Break-Even Earnings for Q2
Other News for PHAT
NR7 appears for PHAT after 3.3% move
Is PHAT signaling a buying opportunity? 20 Day Moving Average Support shows up after declining 3.82%
Is PHAT primed for upward momentum? Crossed Above 20 Day Moving Average shows up after advancing 4.42%
PHAT forms Pocket Pivot on September 30
12 Health Care Stocks Moving In Wednesday's After-Market Session